By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
Developing and commercializing innovative therapies for retinal diseases and other eye conditions10.79M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States51.82M99.75%
China128K0.25%